Immunotech Laboratories(OTC) IMMB

Market Cap$115.00K

Since IPO (2008)-100%

5 Year+100%

1 Year+100%

1 Month+0%

$0.00

+0.00%

+0.00Today

Immunotech Laboratories last closing stock price
Metric	Price	Date
Last close	USD 0.00	2026-07-21

Immunotech Laboratories stock price return by period
Period	Price return	Price at period start	Period start date
1 week	+0%	USD 0.00	2026-07-09
1 month	+0%	USD 0.00	2026-06-16
3 month	+0%	USD 0.00	2026-04-20
Year to date	+100%	USD 0.00	2025-12-19
1 year	+100%	USD 0.00	2025-05-02
3 year	-60%	USD 0.00	2023-06-29
5 year	+100%	USD 0.00	2021-07-16
Since inception	-99.93%	USD 0.30	2008-12-18

Immunotech Laboratories Financials at a Glance

Market Cap

$115.00K

Revenue (TTM)

$0.00

Net Income (TTM)

-$640.25K

EPS (TTM)

$0.00

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

0.43 (Low)

Dividend

$0.00

Beta (Volatility)

0.43 (Low)

Price

$0.00

Volume

10,000

Open

$0.00

Price

$0.00

Volume

10,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

Dividend

$0.00

Beta (Volatility)

0.43 (Low)

Price

$0.00

Volume

10,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.00

52-Week Range

$0.00 - $0.00

Estimated Earnings Date

N/A

IMMB News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immunotech Laboratories

Immunotech Laboratories, Inc. is a biotechnology company focused on developing and commercializing proprietary proteins for treating immuno-related disorders, including HIV and hepatitis. The company’s flagship product, ITV-1, is an immune therapeutic vaccine aimed at modulating the immune system.

Products and Services

ITV-1: Immune therapeutic vaccine for HIV/AIDS and Hepatitis C
Proprietary proteins targeting various immuno-related disorders
Research and development in biotechnology solutions

Growth Outlook

Potential market expansion in HIV and hepatitis treatment sectors
Increased focus on immunotherapy aligns with industry trends
Strategic partnerships may enhance product development capabilities

Financial Highlights

Recent quarterly net income reported at -$119,603
Trailing twelve months (TTM) revenue remains at $0
Current liabilities exceed current assets, indicating liquidity challenges

Immunotech Laboratories, Inc. operates in a niche market with significant growth potential, particularly in the fields of HIV and hepatitis treatment. The company’s innovative approach to immunotherapy positions it well within the biotechnology sector. However, financial performance has shown challenges, with recent quarterly losses and no revenue reported. The company’s current liabilities surpass its assets, raising concerns about liquidity. Despite these challenges, the focus on developing proprietary treatments and potential market expansion could attract interest from investors looking for opportunities in the biotechnology field.

AI Generated • Jul 9, 2026

Industry

Biotechnology

Sector

Health Care

Headquarters

Monrovia, CA 91016, US

IMMB Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-9.01%

Return on Capital

-6.52%

Return on Assets

-4.68%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$115.00K

Shares Outstanding

574.97M

Volume

10.00K

Avg. Volume

4.01K

Financials (TTM)

Gross Profit

-$229.16K

Operating Income

-$486.04K

EBITDA

-$473.44K

Operating Cash Flow

-$301.21K

Capital Expenditure

-$113.00K

Free Cash Flow

-$418.18K

Cash & ST Invst.

$14.29K

Total Debt

$2.42M

Immunotech Laboratories Performance Analysis

Immunotech Laboratories sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2006-09-30	N/A
Q2	2016-06-30	N/A
Q3	2016-09-30	N/A
Q4	2016-12-31	N/A

Immunotech Laboratories sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarter	Period end	QoQ growth
Q3	2006-09-30	-185.7%
Q2	2016-06-30	N/A
Q3	2016-09-30	-103.1%
Q4	2016-12-31	51.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name

Q4 2016YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$76.39K

N/A

Gross Margin

0.00%

N/A

Market Cap

$115.00K

N/A

Market Cap/Employee

$28.75K

N/A

Employees

N/A

Net Income

-$119.60K

-27.2%

EBITDA

-$109.85K

+86.2%

Quarterly Fundamentals

Name

Q4 2016YOY CHG

Total Cash

$14.29K

-2.4%

Total Debt

$2.42M

N/A

Accounts Receivable

$0.00

N/A

Inventory

$0.00

-100.0%

Long Term Debt

$1.65M

N/A

Short Term Debt

$772.89K

N/A

Return on Assets

-4.68%

N/A

Return on Invested Capital

-7.30%

N/A

Free Cash Flow

-$181.47K

-54.4%

Operating Cash Flow

-$68.47K

+38.7%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

CBGLCannabis Global Inc.

CBGLCannabis Global Inc.$0.00+0.00%

BIOIFBiome Grow Inc.

BIOIFBiome Grow Inc.$0.00+0.00%

REFGMedical Cannabis Payment Solutions

REFGMedical Cannabis Payment Solutions$0.00+0.00%

HADVHealth Advance Inc.

HADVHealth Advance Inc.$0.00+0.00%

SPPHSpencer Pharmaceutical Inc.

SPPHSpencer Pharmaceutical Inc.$0.00+0.00%

MHTXManhattan Scientifics, Inc.

MHTXManhattan Scientifics, Inc.$0.00+0.00%

PXYNPraxsyn Corporation

PXYNPraxsyn Corporation$0.00+0.00%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PLTRPalantir Technologies

PLTRPalantir Technologies$162.66+0.29%

SPCXSpace Exploration Technologies

SPCXSpace Exploration Technologies$125.33+0.09%

NVDANvidia

NVDANvidia$211.94+0.03%

INTCIntel

INTCIntel$100.86+0.11%

AMIXAutonomix Medical

AMIXAutonomix Medical$19.50+4.34%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares$8.07+0.03%

NOKNokia

NOKNokia$9.92+0.06%

Questions About IMMB

What is the current price of Immunotech Laboratories?

Immunotech Laboratories is trading at $0.00 per share.

What is the 52-week range for Immunotech Laboratories?

Over the past 52 weeks, Immunotech Laboratories has traded between $0.00 and $0.00.

How much debt does Immunotech Laboratories have?

Immunotech Laboratories total debt is unavailable.

How much cash does Immunotech Laboratories have on hand?

Immunotech Laboratories does not have cash on hand data available.

What is Immunotech Laboratories’s dividend yield?

Immunotech Laboratories does not currently have a dividend yield.

Immunotech Laboratories(OTC) IMMB

Immunotech Laboratories Financials at a Glance

IMMB News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Immunotech Laboratories

IMMB Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Immunotech Laboratories Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About IMMB

What is the current price of Immunotech Laboratories?

What is the 52-week range for Immunotech Laboratories?

How much debt does Immunotech Laboratories have?

How much cash does Immunotech Laboratories have on hand?

What is Immunotech Laboratories’s dividend yield?

Premium Investing Services